RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?

Core Insights - Rigel Pharmaceuticals (RIGL) shares have increased by 59% over the past year, significantly outperforming the industry growth of 2% [1][8] - The company's financial performance is primarily driven by its product Tavalisse, which treats adults with low platelet counts due to chronic immune thrombocytopenia (ITP) [4][6] Financial Performance - Preliminary figures indicate that Rigel expects total revenues of $69.4 million for Q4 2025, representing a 21% year-over-year growth [5] - Tavalisse generated $45.6 million in Q4 sales, reflecting a 47% year-over-year increase and accounting for approximately two-thirds of total revenues [6] - Full-year 2025 product sales are projected to rise by 60% year-over-year to $232 million, exceeding previous guidance [9] - For 2026, Rigel anticipates net product sales of $255–$265 million and expects to achieve positive net income [10] Product Portfolio and Pipeline - Rigel's oncology assets, including Gavreto and Rezlidhia, contributed $10.2 million and $9.6 million in quarterly sales, respectively, diversifying the revenue base [7] - The company is advancing its pipeline with a lead candidate, R289, currently in a phase Ib study for lower-risk myelodysplastic syndrome (MDS) [11] - Rigel is exploring label expansion for Rezlidhia in collaboration with major cancer research institutions [12] - A partnership with Eli Lilly for the development of ocadusertib is also in place, with potential milestone payments and royalties [13] Competitive Landscape - Competition is intensifying, particularly with the FDA approval of Sanofi's Wayrilz for a similar indication in ITP, which could threaten Tavalisse's market position [14] - Gavreto faces competition from Eli Lilly's Retevmo in the RET fusion-positive non-small cell lung cancer (NSCLC) market [15] Valuation and Analyst Outlook - Rigel's stock is trading at a slight premium with a price/sales (P/S) ratio of 2.33 compared to the industry average of 2.28 [16] - Recent estimates for Rigel's 2025 and 2026 EPS have increased, indicating a positive analyst outlook [18] - Despite competitive risks, the company's financial guidance for 2026 reflects confidence in sustaining growth and profitability [19]